Dr James Flanagan, completed his PhD in 2002 at the Queensland Institute of Medical Research in Brisbane, Australia, and has pursued postdoctoral work in Cancer Genetics, Epigenetics and Cancer Epigenetics.
Working in the Division of Cancer Epigenetics Unit, his current work is aimed at investigating germline epigenetic alterations as a mechanism for carcinogenesis funded by Breast Cancer Campaign and Cancer Research UK.He was awarded the British Association of Cancer Research Translational Researcher Award in 2011.
Current research is aimed at investigating epigenetic alterations as a mechanism for carcinogenesis, including projects to define tumour subgroups, identification of biomarkers for cancer risk or prognosis in breast and ovarian cancer and investigating the mechanism of transcriptional regulation by DNA methylation outside of the classical promoter CpG Island. Recent work has focussed on the hypothesis that epigenetic variation may be a driver of cancer risk whether by inherent constitutional variation or as a mediator of other cancer risk factors.
We participate in the London Epigenomics Club
et al., 2017, Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer, Clinical Cancer Research, Vol:23, ISSN:1078-0432, Pages:2213-2222
et al., 2015, Epigenome-wide association study reveals decreased average methylation levels years before breast cancer diagnosis, Clinical Epigenetics, Vol:7, ISSN:1868-7083
et al., 2013, Association of somatic DNA methylation variability with progression-free survival and toxicity in ovarian cancer patients, Annals of Oncology, Vol:24, ISSN:0923-7534, Pages:2813-2818
et al., 2013, Epigenome-wide association study in the European Prospective Investigation into Cancer and Nutrition (EPIC-Turin) identifies novel genetic loci associated with smoking, Human Molecular Genetics, Vol:22, ISSN:0964-6906, Pages:843-851
et al., 2012, Intragenic ATM Methylation in Peripheral Blood DNA as a Biomarker of Breast Cancer Risk, Cancer Research, Vol:72, ISSN:0008-5472, Pages:2304-2313
et al., 2010, DNA Methylome of Familial Breast Cancer Identifies Distinct Profiles Defined by Mutation Status, American Journal of Human Genetics, Vol:86, ISSN:0002-9297, Pages:420-433